

# ForPatients

by Roche

Healthy Male Subjects

## A Study to Evaluate Single Subcutaneous Doses of NXT007 Among Injection Sites Abdomen, Upper Arm, and Thigh in Healthy Male Participants

**Trial Status**  
Recruiting

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT06189508 BP45057

---

The source of the below information is the publicly available website [ClinicalTrials.gov](https://clinicaltrials.gov). It has been summarised and edited into simpler language.

### *Trial Summary:*

This is a Phase I, open-label, non-randomized, parallel-group, single-dose study in healthy adult male participants. The aim is to investigate the relative bioavailability (rBA) of NXT007 among subcutaneous (SC) injection sites (abdomen, upper arm, and thigh) and the absolute bioavailability (aBA) of SC NXT007 administration. In addition, the pharmacodynamic, safety, tolerability, and immunogenicity of a single dose of NXT007 following SC or intravenous (IV) administration are assessed.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT06189508 BP45057**  
Trial Identifiers

---

### *Eligibility Criteria:*

**Gender**  
Male

**Age**  
>=18 Years & <= 45 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---